Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/121714
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: HNO/cGMP-dependent antihypertrophic actions of isopropylamine-NONOate in neonatal rat cardiomyocytes: Potential therapeutic advantages of HNO over NȮ
Author: Irvine, J.
Cao, N.
Gossain, S.
Alexander, A.
Love, J.
Qin, C.
Horowitz, J.
Kemp-Harper, B.
Ritchie, R.
Citation: American Journal of Physiology: Heart and Circulatory Physiology, 2013; 305(3):365-377
Publisher: American Physiological Society
Issue Date: 2013
ISSN: 0363-6135
1522-1539
Statement of
Responsibility: 
Jennifer C. Irvine, Nga Cao, Swati Gossain, Amy E. Alexander, Jane E. Love, Chengxue Qin, John D. Horowitz, Barbara K. Kemp-Harper and Rebecca H. Ritchie
Abstract: Nitroxyl (HNO) is a redox congener of NO. We now directly compare the antihypertrophic efficacy of HNO and NO donors in neonatal rat cardiomyocytes and compare their contributing mechanisms of actions in this setting. Isopropylamine-NONOate (IPA-NO) elicited concentration-dependent inhibition of endothelin-1 (ET1)-induced increases in cardiomyocyte size, with similar suppression of hypertrophic genes. Antihypertrophic IPA-NO actions were significantly attenuated by l-cysteine (HNO scavenger), Rp-8-pCTP-cGMPS (cGMP-dependent protein kinase inhibitor), and 1-H-(1,2,4)-oxodiazolo-quinxaline-1-one [ODQ; to target soluble guanylyl cyclase (sGC)] but were unaffected by carboxy-PTIO (NO scavenger) or CGRP8-37 (calcitonin gene-related peptide antagonist). Furthermore, IPA-NO significantly increased cardiomyocyte cGMP 3.5-fold (an l-cysteine-sensitive effect) and stimulated sGC activity threefold, without detectable NO release. IPA-NO also suppressed ET1-induced cardiomyocyte superoxide generation. The pure NO donor diethylamine-NONOate (DEA-NO) reproduced these IPA-NO actions but was sensitive to carboxy-PTIO rather than l-cysteine. Although IPA-NO stimulation of purified sGC was preserved under pyrogallol oxidant stress (in direct contrast to DEA-NO), cardiomyocyte sGC activity after either donor was attenuated by this stress. Excitingly IPA-NO also exhibited acute antihypertrophic actions in response to pressure overload in the intact heart. Together these data strongly suggest that IPA-NO protection against cardiomyocyte hypertrophy is independent of both NO and CGRP but rather utilizes novel HNO activation of cGMP signaling. Thus HNO acutely limits hypertrophy independently of NO, even under conditions of elevated superoxide. Development of longer-acting HNO donors may thus represent an attractive new strategy for the treatment of cardiac hypertrophy, as stand-alone and/or add-on therapy to standard care.
Keywords: Cardiac hypertrophy; cGMP-dependent protein kinase; nitric oxide; nitroxyl; superoxide
Rights: © 2013 the American Physiological Society
DOI: 10.1152/ajpheart.00495.2012
Grant ID: http://purl.org/au-research/grants/nhmrc/472642
http://purl.org/au-research/grants/nhmrc/472673
Appears in Collections:Aurora harvest 4
Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.